Related Experiment Video
Updated: Oct 26, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Pediatric epidermolysis bullosa acquisita: A review
1University of Central Florida College of Medicine, Orlando, FL, USA.
Insights
Pediatric Epidermolysis Bullosa Acquisita (EBA) is a rare autoimmune blistering disease. Reviewing 40 cases shows mucosal involvement and a favorable prognosis with treatments like corticosteroids and dapsone.
Area of Science:
- Dermatology
- Autoimmune Diseases
- Pediatrics
Background:
- Epidermolysis bullosa acquisita (EBA) is a rare acquired autoimmune blistering skin disorder.
- Childhood EBA is exceptionally rare, necessitating focused clinical review.
Purpose of the Study:
- To identify and analyze cases of pediatric EBA.
- To report on the clinical features, treatment, and course of childhood EBA.
Main Methods:
- A comprehensive literature review was performed using MEDLINE®.
- Search terms focused on juvenile epidermolysis bullosa acquisita.
Main Results:
- Forty cases of pediatric EBA were identified.
- Mucosal tissues were affected in 29 out of 40 cases.
- Treatment commonly involved systemic corticosteroids combined with dapsone, with a favorable prognosis in most cases.
Conclusions:
- Childhood EBA, though rare, requires consideration in the differential diagnosis of pediatric blistering diseases.
- Effective management strategies exist, leading to remission or control in the majority of identified cases.
Abstract:
Epidermolysis bullosa acquisita (EBA) is an acquired autoimmune blistering skin disorder that is rare in adults and even rarer in childhood. This review aims to identify cases of pediatric EBA and report their clinical features and course. Our literature review was conducted in MEDLINE® using the search terms related to juvenile epidermolysis bullosa acquisita. We identified 40 cases of pediatric EBA. Mucosal tissues were affected in 29 out of 40 cases. Treatment mostly consisted of a systemic corticosteroid combined with dapsone. Prognosis is favorable with 17 of 40 cases achieving complete remission, 9 of 40 with complete control with therapy, 12 of 40 with partial control with therapy, 1 of 40 with no response to therapy, and 1 of 40 terminating treatment early. Though it is a rare condition, childhood EBA should still be included in the differential diagnosis of pediatric blistering diseases.
Related Concept Videos
Clinical Applications of Epidermal Stem Cells
Renewal of Skin Epidermal Stem Cells
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Desmosomes

